NewAmsterdam Pharma Company NVNASDAQ:NAMS
- LAST PRICE13.2900
- TODAY'S CHANGE (%)-0.1300 (-0.9687%)
- Bid / Lots13.2000/ 25
- Ask / Lots13.5200/ 7
- Open / Previous Close13.0700 / 13.4200
- Day Range
- 52 Week Range
- Volume2,125
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAMS |
|---|---|---|
| 01:50 ET | 100 | 13.07 |
| 02:13 ET | 200 | 13.29 |
| 02:29 ET | 200 | 13.215 |
| 02:31 ET | 100 | 13.29 |
Mar 1, 2023
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference, from 8:00AM ET on Wednesday Mar 01, 2023 by GlobeNewswire
8:00AM ET on Wednesday Mar 01, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NewAmsterdam Pharma Company NV | 1.1B | -64.8x | --- |
Replimune Group Inc | 1.1B | -6.7x | --- |
Viridian Therapeutics Inc | 1.1B | -6.3x | --- |
Zentalis Pharmaceuticals Inc | 1.0B | -3.8x | --- |
Prime Medicine Inc | 1.2B | -8.1x | --- |
Cassava Sciences Inc | 1.0B | -12.6x | --- |
Company Information
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Contact Information
- Headquarters
- Gooimeer 2-35NAARDEN, Netherlands 1411 DC
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 81.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.21 |
Book Value | $7.42 |
P/E Ratio | -64.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
